Cardiovascular Safety Study of Magnevist® Injection at Two Dose Levels and Two Injection Rates in Normal Subjects
Status:
Completed
Trial end date:
2004-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine what effect Magnevist (gadopentetate dimeglumine)
injection has on the way the heart conducts the electrical impulses that allow it to beat
effectively. The study will compare Magnevist injection's effect to that of placebo (a saline
injection).
Phase:
Phase 1
Details
Lead Sponsor:
Bayer
Treatments:
Moxifloxacin Norgestimate, ethinyl estradiol drug combination